Skip to main content
. 2018 Mar 30;3(3):3608–3616. doi: 10.1021/acsomega.8b00220

Figure 2.

Figure 2

In vitro study using the designed PIPs. (A) Luciferase reporter assay model of the PIPs. In Notch-active models, the NICD translocates into the nucleus and operates with RBPJ to activate the downstream genes. PIP-RBPJ blocks the binding of RBPJ and results in the suppression of the gene expression. (B) Effect of PIPs on pHES1-L luciferase activity. PIP-RBPJ-1 decreases pHES1-L luciferase activity in a concentration-dependent manner. Three biological replicates were performed, and the mean ± SD are indicated, *P < 0.05, **P < 0.01. (C) Chromatin immunoprecipitation (ChIP) analysis using the RBPJ antibody in the promoter region of HES1 revealed a decrease in the amount of the promoter sequence in the PIP-RBPJ-1-treated hNSCs and not the dimethyl sulfoxide (DMSO)-treated hNSCs.